Propranolol use tied to increased mortality in child-pugh B, C

April 10, 2016

(HealthDay)—For patients with Child-Pugh B and C, propranolol use is associated with increased mortality, according to a letter to the editor published online March 26 in Hepatology.

Georgios N. Kalambokis, M.D., from the University of Ioannina in Greece, and colleagues conducted a retrospective assessment of 96 Child-Pugh B and 75 Child-Pugh C patients with newly diagnosed cirrhosis who presented with clinically-evident ascites between January 2000 and December 2012; 28 patients had a model for end-stage liver disease (MELD) score of ≥18. Concomitant with diagnosis of cirrhosis, propranolol was initiated in 56 Child-Pugh B and 45 Child-Pugh C patients with varices (17 patients had a MELD score ≥18).

The researchers found that four patients subsequently developed refractory ascites (all Child-Pugh C; three propranolol treated). Forty-four and 57 Child-Pugh B and C patients, respectively (34 and 41 propranolol-treated, respectively), died of cirrhosis-related complications. After two years of follow-up, propranolol-treated Child-Pugh B patients showed significantly higher . After six months of follow-up, mortality became increasingly significant in propranolol-treated Child-Pugh C patients or those with a MELD score ≥18, compared with non-treated patients. The mean survival was 10.1 ± 1.1 and 15 ± 1.4 months in -treated and non-treated Child-Pugh C patients, respectively (P = 0.03).

"Our observations justify the concerns recently raised over non-selective β-blockers treatment in with decompensated ," the authors write.

Explore further: Continued metformin beneficial for diabetes with cirrhosis

More information: Full Text (subscription or payment may be required)

Related Stories

Continued metformin beneficial for diabetes with cirrhosis

December 9, 2014
(HealthDay)—Continuation of metformin therapy may improve survival in diabetes patients who are diagnosed with cirrhosis, according to research published in the December issue of Hepatology.

Propranolol for hemangiomas doesn't impair infant growth

March 21, 2016
(HealthDay)—For infantile hemangiomas, systemic propranolol appears safe and does not impair physical growth, according to a study published online March 6 in the Journal of Dermatology.

Heart surgery safe for compensated cirrhosis patients

April 27, 2012
(HealthDay) -- Patients with compensated cirrhosis, defined by a Child-Pugh (CP) score of

No need to avoid statins in hep C compensated cirrhosis

February 10, 2016
(HealthDay)—Statin use is associated with decreased risk of cirrhosis decompensation and death in patients with hepatitis C virus (HCV)-related compensated cirrhosis, according to research published in the February issue ...

Propranolol, doxycycline combo safe, effective in rosacea

January 13, 2015
(HealthDay)—For patients with rosacea, combination treatment with propranolol and doxycycline is effective and safe, according to a study published in the January issue of the Journal of Dermatology.

Serious adverse drug reactions rare from certain treatment for vascular tumor in infants

January 26, 2016
Sorilla Prey, M.D., of the Université de Bordeaux, France and colleagues examined the safety of propranolol therapy in treating infantile hemangioma, a vascular tumor characterized by rapid growth during the first weeks ...

Recommended for you

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.